Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Liquidia Corporation - Common Stock (NQ:LQDA)

14.92 -0.08 (-0.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Friday's after hours session: top gainers and losers
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
These Analysts Boost Their Forecasts On Liquidia
Via Benzinga
Breaking Down Liquidia: 12 Analysts Share Their Views
Via Benzinga
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge
Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Earnings Scheduled For May 8, 2025
Via Benzinga
Breaking Down Liquidia: 4 Analysts Share Their Views
Via Benzinga
The Analyst Landscape: 11 Takes On Liquidia
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod
The company’s proprietary dry-powder formulation, supported by Phase 3 data, is viewed as a promising alternative to United Therapeutics’ Tyvaso, though legal challenges remain pending. 
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Where Liquidia Stands With Analysts
Via Benzinga
Breaking Down Liquidia: 4 Analysts Share Their Views
Via Benzinga
What 4 Analyst Ratings Have To Say About Liquidia
Via Benzinga
Uncovering Potential: Liquidia's Earnings Preview
Via Benzinga
Evaluating Liquidia: Insights From 14 Financial Analysts
Via Benzinga
These Analysts Cut Their Forecasts On Liquidia
Via Benzinga
Why Liquidia Corporation Shares Are Moving Lower Monday
Liquidia announced that the Food and Drug Administration granted tentative approval of YUTREPIA. 
Via Benzinga
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Earnings Scheduled For March 19, 2025
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
Via Benzinga
Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase
Via Benzinga
Exposures Fossil Fuels
Petco, AppLovin, Dave & Buster's And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Jim Cramer Praises PayPal CEO Alex Chriss: 'Financial Techs Have Come Back In Style'
PayPal CEO Alex Chriss "is a very good manager," Cramer said. Plus: AST SpaceMobile, Flutter Entertainment and more. 
Via Benzinga
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38%
The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.